Dyax Corp. (DYAX) Announces Dosing Of First Subject In Phase 1b Trial Of DX-2930 In Patients With Hereditary Angioedema
5/28/2014 8:50:24 AM
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced dosing of the first subject in its Phase 1b clinical study of DX-2930 in hereditary angioedema (HAE) patients. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of multiple subcutaneous administrations of DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein. Dyax, a biopharmaceutical company focused on HAE and other plasma-kallikrein-mediated disorders, is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks.
Help employers find you! Check out all the jobs and post your resume.
comments powered by